Inhibition of 3-Phosphoinositide-Dependent Kinase 1 Improves Age-Associated Epidermal Dysfunction.
- 1Research and Innovation Center, AMOREPACIFIC, Yongin-si, Gyeonggi-do, Korea.
- 2Department of Dermatology, Korea University Ansan Hospital, Ansan, Korea.
Abstract
Epidermal aging is characterized by impaired homeostasis, including reduced cell proliferation, aberrant differentiation, deterioration of the dermal-epidermal junction (DEJ), and compromised barrier function. Accumulating evidence suggests that these alterations arise not solely from intrinsic stem cell loss but from disruption of regulatory signalling networks governing epidermal function. In this study, we investigate whether inhibition of 3-phosphoinositide-dependent kinase-1 (PDK1), a central regulator of aging-related AKT/mTOR and NF-κB signalling, is associated with improved epidermal homeostasis through functional enhancement of autophagy. Using primary normal human epidermal keratinocytes (NHEKs) from young and old donors, 3-dimensional organotypic epidermal skin equivalents (SE), and chronologically aged human skin, we found that aged epidermis exhibited markedly reduced autophagy activity accompanied by defective differentiation, impaired keratinocyte proliferation, and loss of key stem cell niche components at the DEJ. Pharmacological inhibition of PDK1 using selective PDK1 inhibitors (BX795, GSK2334470) or a plant-derived inhibitor (kaempferol tetrasaccharide, KT1) formulated as Camellia japonica seed fraction (CF) suppressed AKT/mTOR and NF-κB signalling in aged keratinocytes, which was accompanied by increased autophagy-related markers and improved entry into differentiation. In addition, PDK1 inhibition increased basal keratinocyte proliferation, increased epidermal thickness, and improved DEJ components. In a proof-of-concept clinical study, topical application of CF, a botanical fraction containing KT1, was associated with improvements in epidermal autophagy, differentiation, DEJ integrity, and barrier function in aged human skin. Collectively, these findings identify a regulatory role of PDK1 within the epidermis and provide proof-of-concept evidence that pharmacological modulation of PDK1 activity exhibits potential for mitigating age-associated epidermal dysfunction.
Related
- Endoplasmic Reticulum Autophagy Enhancement Alleviates Synaptic Plasticity Dysfunction and Ameliorates Cognitive Impairment in SAE Mice by Relieving STING‐Associated Inhibition of PKM2 Activity
- Dose-dependent efficacy and renal safety of pemafibrate versus fenofibrate in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hypertriglyceridemia: a multicenter randomized controlled, open label trial
- Multi-cohort and single-nucleus transcriptomics identify a five-gene lactylation-related panel and a disease-dependent hepatocyte glycolysis-lactylation-related expression program in metabolic dysfunction-associated steatohepatitis.
- Dapagliflozin Attenuates Post-Infarction Myocardial Fibrosis Associated With the Inhibition of NLRP3-Dependent Inflammation
- Keratinocyte TMEM79 protects early life epidermal homeostasis and restrains STING-dependent skin inflammation
BibTeX
@article{cho2026inhibition,
title = {{Inhibition of 3-Phosphoinositide-Dependent Kinase 1 Improves Age-Associated Epidermal Dysfunction.}},
author = {Si-Young Cho and Hyung-Su Kim and Seung-Hun Kim and Kyung-Mi Joo and Sung Yeon Cho and Sang Wook Son and Heung-Soo Baek and Hyoung-June Kim and Jaeyoung Ko and A Young Kim},
journal = {Experimental dermatology},
year = {2026},
month = oct,
doi = {10.1111/exd.70379},
url = {https://europepmc.org/article/MED/42963119},
note = {CC BY},
}
RIS
TY - JOUR
TI - Inhibition of 3-Phosphoinositide-Dependent Kinase 1 Improves Age-Associated Epidermal Dysfunction.
AU - Si-Young Cho
AU - Hyung-Su Kim
AU - Seung-Hun Kim
AU - Kyung-Mi Joo
AU - Sung Yeon Cho
AU - Sang Wook Son
AU - Heung-Soo Baek
AU - Hyoung-June Kim
AU - Jaeyoung Ko
AU - A Young Kim
PY - 2026
DA - 2026/10/30
JO - Experimental dermatology
DO - 10.1111/exd.70379
UR - https://europepmc.org/article/MED/42963119
AB - Epidermal aging is characterized by impaired homeostasis, including reduced cell proliferation, aberrant differentiation, deterioration of the dermal-epidermal junction (DEJ), and compromised barrier function. Accumulating evidence suggests that these alterations arise not solely from intrinsic stem cell loss but from disruption of regulatory signalling networks governing epidermal function. In this study, we investigate whether inhibition of 3-phosphoinositide-dependent kinase-1 (PDK1), a central regulator of aging-related AKT/mTOR and NF-κB signalling, is associated with improved epidermal homeostasis through functional enhancement of autophagy. Using primary normal human epidermal keratinocytes (NHEKs) from young and old donors, 3-dimensional organotypic epidermal skin equivalents (SE), and chronologically aged human skin, we found that aged epidermis exhibited markedly reduced autophagy activity accompanied by defective differentiation, impaired keratinocyte proliferation, and loss of key stem cell niche components at the DEJ. Pharmacological inhibition of PDK1 using selective PDK1 inhibitors (BX795, GSK2334470) or a plant-derived inhibitor (kaempferol tetrasaccharide, KT1) formulated as Camellia japonica seed fraction (CF) suppressed AKT/mTOR and NF-κB signalling in aged keratinocytes, which was accompanied by increased autophagy-related markers and improved entry into differentiation. In addition, PDK1 inhibition increased basal keratinocyte proliferation, increased epidermal thickness, and improved DEJ components. In a proof-of-concept clinical study, topical application of CF, a botanical fraction containing KT1, was associated with improvements in epidermal autophagy, differentiation, DEJ integrity, and barrier function in aged human skin. Collectively, these findings identify a regulatory role of PDK1 within the epidermis and provide proof-of-concept evidence that pharmacological modulation of PDK1 activity exhibits potential for mitigating age-associated epidermal dysfunction.
SN - 0906-6705
SN - 1600-0625
ER -